[go: up one dir, main page]

MX2009004871A - Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. - Google Patents

Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.

Info

Publication number
MX2009004871A
MX2009004871A MX2009004871A MX2009004871A MX2009004871A MX 2009004871 A MX2009004871 A MX 2009004871A MX 2009004871 A MX2009004871 A MX 2009004871A MX 2009004871 A MX2009004871 A MX 2009004871A MX 2009004871 A MX2009004871 A MX 2009004871A
Authority
MX
Mexico
Prior art keywords
unit dosage
methods
weight loss
drug
loss medications
Prior art date
Application number
MX2009004871A
Other languages
English (en)
Inventor
Eckard Weber
Gary Tollefson
Anthony A Mckinney
Rick Soltero
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39402403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of MX2009004871A publication Critical patent/MX2009004871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se revelan métodos y sistemas para la administración de farmacéuticos que usan un paquete de dosificación unitario que incluye una primera dosificación unitaria que tiene un primer fármaco y un segundo fármaco, una segunda dosificación unitaria que tiene el primer fármaco y el segundo fármaco, en donde la segunda dosificación unitaria incluye una diferente cantidad del segundo fármaco que la primera dosificación unitaria y un paquete de dosificación unitario está configurado para retener la primera dosificación unitaria y la segunda dosificación unitaria. En modalidades preferidas, los métodos y sistemas y métodos son usados para la administración de medicaciones de pérdida de peso.
MX2009004871A 2006-11-09 2007-11-08 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. MX2009004871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86515906P 2006-11-09 2006-11-09
PCT/US2007/084178 WO2008060964A2 (en) 2006-11-09 2007-11-08 Unit dosage package and methods for administering weight loss medications

Publications (1)

Publication Number Publication Date
MX2009004871A true MX2009004871A (es) 2009-06-16

Family

ID=39402403

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2009004871A MX2009004871A (es) 2006-11-09 2007-11-08 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX2013009433A MX343867B (es) 2006-11-09 2007-11-08 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX2023006414A MX2023006414A (es) 2006-11-09 2009-05-07 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2013009433A MX343867B (es) 2006-11-09 2007-11-08 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX2023006414A MX2023006414A (es) 2006-11-09 2009-05-07 Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.

Country Status (14)

Country Link
US (8) US20080110792A1 (es)
EP (1) EP2088998A2 (es)
JP (1) JP2010508997A (es)
KR (6) KR20140088619A (es)
CN (1) CN101573103A (es)
AR (1) AR063958A1 (es)
AU (1) AU2007319472B2 (es)
CA (1) CA2668885C (es)
CL (1) CL2007003246A1 (es)
IL (1) IL198578A0 (es)
MX (3) MX2009004871A (es)
RU (1) RU2009116834A (es)
TW (1) TW200829235A (es)
WO (1) WO2008060964A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
CN101496042A (zh) 2006-05-02 2009-07-29 普罗秋斯生物医学公司 患者定制的治疗方案
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
JP5916277B2 (ja) 2006-10-25 2016-05-11 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能な制御活性化識別子
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) * 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
WO2008063626A2 (en) 2006-11-20 2008-05-29 Proteus Biomedical, Inc. Active signal processing personal health signal receivers
CN101686800A (zh) 2007-02-01 2010-03-31 普罗秋斯生物医学公司 可摄入事件标记器系统
CA3000257C (en) 2007-02-14 2020-04-28 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
EP4011289A1 (en) 2007-09-25 2022-06-15 Otsuka Pharmaceutical Co., Ltd. In-body device with virtual dipole signal amplification
WO2009158114A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2696984T3 (es) 2008-07-08 2019-01-21 Proteus Digital Health Inc Infraestructura de datos de marcadores de eventos de ingestión
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045416A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
AU2010203625A1 (en) 2009-01-06 2011-07-21 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
WO2010151503A2 (en) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2011008490A2 (en) * 2009-06-29 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
PL3222280T3 (pl) 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
CA2819003A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
AR086395A1 (es) * 2011-05-11 2013-12-11 Kirax Corp Envase para el tratamiento de patologias
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
EP2734973A4 (en) 2011-07-21 2015-07-01 Proteus Digital Health Inc MOBILE COMMUNICATION DEVICE, SYSTEM AND METHOD
WO2013078416A2 (en) * 2011-11-23 2013-05-30 Proteus Digital Health, Inc. Apparatus, system, and method to promote behavior change based on mindfulness methodologies
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3968263A1 (en) 2013-06-04 2022-03-16 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
GB2530110A (en) * 2014-11-03 2016-03-16 Multi Packaging Solutions Uk Ltd Packaging
WO2017087373A1 (en) * 2015-11-16 2017-05-26 Actavis Elizabeth Llc Modified release abuse deterrent tablet
CN111772582A (zh) 2016-07-22 2020-10-16 普罗秋斯数字健康公司 可摄入事件标记的电磁感测和检测
WO2020172484A1 (en) * 2019-02-21 2020-08-27 Accoy Pharmaceuticals, Inc. Point of care pharmacy app controlled blister pack drug dispenser
WO2021053542A1 (en) * 2019-09-20 2021-03-25 Dr. Reddy’S Laboratories Limited Pharmaceutical compositions for obesity management
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
US11759393B2 (en) * 2020-11-09 2023-09-19 Hassan Zakaria Prescription medicine packaging system and method for using same to provide range of compliance options
CN113069438A (zh) * 2021-04-01 2021-07-06 沈阳欣瑞制药有限公司 含有二甲双胍和安非他酮的药物组合物及其用途
CN117693335A (zh) * 2021-05-11 2024-03-12 罗斯研究中心有限责任公司 组合治疗方法
US12046341B2 (en) 2021-10-05 2024-07-23 Bradford Rabin Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3942641A (en) * 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4089855A (en) 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4218433A (en) 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
IL58649A (en) * 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4895845A (en) 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
NL8800823A (nl) 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
EP0294028B1 (en) 1987-05-04 1993-09-01 Eli Lilly And Company Fluoxetine useful for the treatment of diabetes
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
EP0483152A4 (en) 1989-05-09 1992-12-02 Whitby Research Incorporated A method of reducing body weight and food intake using a dopamine d2 receptor agonist
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
ATE99943T1 (de) 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
FR2657350B1 (fr) 1990-01-19 1992-05-15 Centre Nat Rech Scient Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
DE69525847T2 (de) 1994-09-19 2002-09-05 Dupont Pharmaceuticals Co., Wilmington Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
AU6824996A (en) 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
WO1997041873A1 (en) 1996-05-07 1997-11-13 Ergo Research Corporation Method and composition for the treatment of lipid and glucose metabolism disorders
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
PT915697E (pt) 1996-06-28 2003-02-28 Ortho Mcneil Pharm Inc Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
CN1155410C (zh) 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6342515B1 (en) 1997-12-26 2002-01-29 Dainippon Pharmaceutical Co., Ltd. Remedy for neurodegenerative diseases
AP1229A (en) 1998-01-21 2003-12-04 Glaxo Group Ltd Pharmaceutically active morpholinol.
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CZ20013061A3 (cs) 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů
US20030035840A1 (en) 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
IL145712A0 (en) 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ATE397581T1 (de) 1999-04-06 2008-06-15 Sepracor Inc O-desmethylvenlafaxin-succinat
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
CA2377330C (en) 1999-06-14 2009-11-24 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6034322A (en) * 1999-07-01 2000-03-07 Space Systems/Loral, Inc. Solar cell assembly
SK286667B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu chronického únavového syndrómu
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
AU7750100A (en) 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
JP2003520234A (ja) 2000-01-22 2003-07-02 アルバート シャルマン 薬物中毒の治療方法
US20020090615A1 (en) 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
DE60119696T2 (de) 2000-03-15 2007-01-25 Wolfgang Ross Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
AU2001247474A1 (en) 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
JP2004518718A (ja) 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗糖尿病薬および抗痙攣薬を含んで成る併用療法
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
EP1404342A1 (en) 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
ATE474559T1 (de) 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US6462237B1 (en) 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
AU2002319774B2 (en) 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
JP2003060134A (ja) 2001-08-17 2003-02-28 Polymatech Co Ltd 熱伝導性シート
US20030044462A1 (en) 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AU2002358270A1 (en) 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
PL371596A1 (en) 2002-05-17 2005-06-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
WO2004009015A2 (en) 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US6702097B1 (en) 2002-09-04 2004-03-09 Owens-Brockway Glass Container Inc. Method of and apparatus for transferring articles from a fixed position to a moving conveyor
JP4878839B2 (ja) 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
EP1539145A2 (en) 2002-09-13 2005-06-15 Eisai Co., Ltd. Method of treating tremors
AU2003268380A1 (en) 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
RU2005122008A (ru) 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
US20040158194A1 (en) 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
JP2006522099A (ja) 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
CA2525323A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005009417A1 (en) 2003-07-21 2005-02-03 Noven Pharmaceuticals, Inc. Composition and method for controlling grug delivery from silicone adhesive blends
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
ES2318330T3 (es) 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
NZ544281A (en) 2003-08-08 2008-07-31 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
KR100965580B1 (ko) * 2003-08-21 2010-06-23 엘지디스플레이 주식회사 액정표시장치와 그의 구동방법
AU2004266043B2 (en) 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
US20050043773A1 (en) 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
AU2004277898B2 (en) 2003-09-25 2009-04-02 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050112198A1 (en) 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US20050232990A1 (en) 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
SE0400378D0 (sv) 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
CN1964704A (zh) 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20060100205A1 (en) 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
CA2576505A1 (en) * 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
AU2005280058B2 (en) 2004-08-25 2010-09-02 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2575764A1 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
AU2005305140A1 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as CB1 antagonists
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20070078135A1 (en) 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
US20060246131A1 (en) 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
CN101208092A (zh) 2005-05-31 2008-06-25 奥雷西根治疗公司 用于处理精神障碍的方法和组合物
US20070021352A1 (en) 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
MX2008001136A (es) 2005-07-27 2008-03-13 Orexigen Therapeutics Inc Composiciones para afectar la perdida de peso.
US20070048237A1 (en) * 2005-08-26 2007-03-01 Song Leila S Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007062228A1 (en) 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
WO2007064586A1 (en) 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
CA2819003A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
CA2668885A1 (en) 2008-05-22
AR063958A1 (es) 2009-03-04
KR20160072276A (ko) 2016-06-22
US20190282503A1 (en) 2019-09-19
CN101573103A (zh) 2009-11-04
US20110059170A1 (en) 2011-03-10
US8722085B2 (en) 2014-05-13
WO2008060964A3 (en) 2008-09-12
MX2023006414A (es) 2023-06-15
CA2668885C (en) 2016-08-02
RU2009116834A (ru) 2010-12-20
US20240366513A1 (en) 2024-11-07
KR20150082689A (ko) 2015-07-15
KR20140088619A (ko) 2014-07-10
EP2088998A2 (en) 2009-08-19
KR20180066272A (ko) 2018-06-18
US10307376B2 (en) 2019-06-04
WO2008060964A2 (en) 2008-05-22
US20200352863A1 (en) 2020-11-12
AU2007319472B2 (en) 2013-01-17
US9125868B2 (en) 2015-09-08
JP2010508997A (ja) 2010-03-25
CL2007003246A1 (es) 2008-03-24
KR20090090316A (ko) 2009-08-25
US20080110792A1 (en) 2008-05-15
AU2007319472A1 (en) 2008-05-22
IL198578A0 (en) 2010-02-17
US20160193152A1 (en) 2016-07-07
TW200829235A (en) 2008-07-16
US20180360760A1 (en) 2018-12-20
MX343867B (es) 2016-11-25
AU2007319472A2 (en) 2009-07-02
US20140322318A1 (en) 2014-10-30
US12048769B2 (en) 2024-07-30
KR20170077291A (ko) 2017-07-05

Similar Documents

Publication Publication Date Title
MX2009004871A (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
WO2008146178A3 (en) A novel tablet dosage form
UA99431C2 (uk) Спосіб збирання пристрою для доставки ліків та пристрій для доставки ліків
BRPI0719009B8 (pt) mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos
TR201903693T4 (tr) ilaç dağıtım cihazına yönelik dozlama ve tahrik mekanizması.
JO3323B1 (ar) صور جرعة صيدلانية
MY148971A (en) Improvements in and relating to drive mechanisms suitable for use in drug delivery devices
IN2011CN08926A (es)
MX343358B (es) Tabletas de acetato de ulipristal.
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
WO2012052853A3 (en) Oral dosing device for administration of medication
WO2007103293A3 (en) Ethanol-resistant sustained release formulations
MX2014003186A (es) Formulaciones farmacéuticas resistentes a la manipulación.
AU2012310251A8 (en) Tamper resistant immediate release formulations
AU2010212580A8 (en) Stable pharmaceutical composition for atherosclerosis
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
EA201391689A1 (ru) Система доставки лекарственного средства
PH12014501408A1 (en) Immediate release multi unit pellet system
WO2012145575A3 (en) Therapy for leukemia
MX2009006872A (es) Sistemas de empaquetado farmaceutico para el cumplimiento mejorado del paciente.
TN2009000088A1 (en) Packaging system for pharmaceutical compositions and kit for intravenous administration
WO2009152144A3 (en) All day rhinitic condition treatment regimen
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
TW200628182A (en) Injection device for administering a medication liquid
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal